Durect Reports Q3 Loss, Misses Revenue Estimates
MDWD Stock | USD 17.18 0.57 3.21% |
About 62% of Mediwound's investor base is looking to short. The analysis of overall sentiment of trading Mediwound stock suggests that many investors are alarmed at this time. The current market sentiment, together with Mediwound's historical and current headlines, can help investors time the market. In addition, many technical investors use Mediwound stock news signals to limit their universe of possible portfolio assets.
Mediwound |
Durect delivered earnings and revenue surprises of 17.65 percent and 2.43, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock
Read at zacks.com
Mediwound Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Mediwound can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Mediwound Fundamental Analysis
We analyze Mediwound's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Mediwound using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Mediwound based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Owned By Institutions
Shares Owned By Institutions Comparative Analysis
Mediwound is currently under evaluation in shares owned by institutions category among its peers. Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
Mediwound Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Mediwound stock to make a market-neutral strategy. Peer analysis of Mediwound could also be used in its relative valuation, which is a method of valuing Mediwound by comparing valuation metrics with similar companies.
Peers
Mediwound Related Equities
SWTX | SpringWorks Therapeutics | 6.02 | ||||
KRON | Kronos Bio | 3.09 | ||||
OCUL | Ocular Therapeutix | 2.25 | ||||
MRUS | Merus BV | 2.12 | ||||
KROS | Keros Therapeutics | 1.28 | ||||
SNDX | Syndax Pharmaceuticals | 0.80 | ||||
FHTX | Foghorn Therapeutics | 0.64 | ||||
MLYS | Mineralys Therapeutics, | 0.54 | ||||
AVTE | Aerovate Therapeutics | 0.74 | ||||
STRO | Sutro Biopharma | 0.98 | ||||
DYAI | Dyadic International | 1.02 | ||||
NKTX | Nkarta | 1.63 | ||||
RNA | Avidity Biosciences | 2.01 | ||||
CRNX | Crinetics Pharmaceuticals | 2.12 | ||||
VCYT | Veracyte | 2.12 | ||||
LYEL | Lyell Immunopharma | 2.94 | ||||
GLUE | Monte Rosa | 5.22 | ||||
SANA | Sana Biotechnology | 5.71 | ||||
INBX | Inhibrx | 6.11 | ||||
REPL | Replimune | 6.82 | ||||
GBIO | Generation Bio | 8.77 |
Complementary Tools for Mediwound Stock analysis
When running Mediwound's price analysis, check to measure Mediwound's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mediwound is operating at the current time. Most of Mediwound's value examination focuses on studying past and present price action to predict the probability of Mediwound's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mediwound's price. Additionally, you may evaluate how the addition of Mediwound to your portfolios can decrease your overall portfolio volatility.
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets |